Plus therapeutics to present at the gordon research conference radionuclide theranostics for the management of cancer

Austin, texas, july 02, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced that melissa moore, ph.d., vice president, clinical research and development, will give a presentation at 11:30 a.m.
pstv Ratings Summary
pstv Quant Ranking